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Methods
 A review of the literature was conducted using PubMed, EMBASE, and 
various public data sources. Search keywords related to the history and 
efficacy of safe injection facilities (SIFs), their implementation to 
Philadelphia, and other related terms were used. 
 Semi-structured discussion sessions were conducted among members of 
the Institute of Clinical Bioethics at Saint Joseph’s University, resident 
physicians at Mercy Health System, and medical students at the 
Philadelphia College of Osteopathic Medicine (PCOM). Topics of 
discussion included the risks, benefits, and ethics involved in initiating a 
CUES in Philadelphia, with research regarding past SIFs being uses as a 
comparative model
 Each team conducted independent reviews of different aspects 
regarding a proposed SIF in Philadelphia and presented their findings 
back to the group.
Due to the effectiveness of Insite in Vancouver, our research seeks to 
consider Comprehensive User Engagement Sites (CUES) as a viable option 
in response to the growing Opioid Crisis in Philadelphia. As an extension of 
the framework provided by Insite, the CUES model would offer additional 
resources such as: 
 Wound Care: It has been estimated that the annual savings of a CUES 
skin and soft tissue service could save between $1.5-$1.8 million 
annually. The integration of a wound care service with medical 
education provides an opportunity for students to gain practical 
experience, while witnessing first-hand the effects of opioid usage 
within marginalized populations.
 Needle Exchange Program: between 1999 and 2014 the needle   
exchange program reduced the number of HIV transmission cases 
related to needle sharing from 46% in 1992 to 5.4% in 2014. 
 Naloxone (Narcan®) distribution: The use of Narcan can further reduce 
the current Philadelphia healthcare cost of $92,408 per hospitalization 
with an average length of stay of 7-10 days attributed to overdose.
Applying the results from Vancouver’s Insite to a Philadelphia 
Comprehensive User Engagement Site, the facility has the potential to be 
highly successful. Experts from Insite project that a facility in Philadelphia 
could lead to between 3 and 48 averted cases of HIV infection annually, 15 
to 213 averted cases of Hepatitis C cases annually, and prevent 24 to 76 
overdose related deaths annually. 
In October of 2017, the United States Department of Health and Human 
Services declared a national public health emergency because of the 
country’s opioid crisis. Opioid abuse has become a daunting public health 
problem across the nation, and especially in the Philadelphia region. There 
may be as many as 70,000 heroin users in the Philadelphia area along with 
50,000 people that have misused prescription painkillers. In 2017, the 
number of deaths caused by drug overdoses in Philadelphia were four 
times greater than the number of deaths by homicide. Overall, the opioid 
crisis costs the city an estimated $26 million a year or more. Combating 
this problem has proven to be a challenge for health officials, and it is 
imperative that measures are taken to decrease morbidity and mortality 
related to opioid drug abuse and decrease healthcare costs. The Task Force 
to Combat the Opioid Epidemic, created by Philadelphia mayor James 
Kenney, produced a list of possible solutions that included implementing 
a Comprehensive User Engagement Site (CUES) that would provide 
medical resources and assistance for opioid users. This facility would allow 
people who inject drugs (PWID) to do so under the supervision of trained 
healthcare professionals. PWID would have access to clean needles, 
overdose medications, patient education, and opportunities for recovery. 
A similar safe injection facility (SIF) has been operating in Vancouver for 
many years, and has had success in addressing both the costs and 
complications associated with opioid abuse in Canada. This study analyzed 
the clinical, ethical, and economic considerations associated with a 
potential CUES site in Philadelphia, using the Vancouver SIF as a model for 
comparison.
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The Reality In Philadelphia:
2016:  907 deaths were documented to be caused by drug overdoses
 Of those, 80% were attributed to Opioids
2017: 1217 unintentional drug overdose deaths occurred in Philadelphia 
 Fatal drug overdoses increased by 34% compared to 2016
 Opioids were found in 88% of drug deaths in 2017, up from 80% in 2016
 935 Cases of secondary conditions
arose from Needle Sharing
 Predicted that there are 4X as 
many deaths from Overdose 
compared to homicides
Insite: Canada’s First Legally sanctioned Supervised Injection Facility
2003-Present: 
 Insite has served as a scientific pilot and has resulted in :
 Reduction in public disorder (figure 2)
 Reduction in infectious disease transmission 
 Reduction in incidence of drug overdose 
 Increased participation in external treatment programs 
 Did NOT result in an increase in Crime 
 Overall Cost effective 
 There have been 48,798 clinical treatment visits
 6,440 overdose interventions, and 0 deaths. 
Figure 1.
Figure 2: 6 weeks before and 12 weeks after 
facility opened. Dotted line represents opening 
of facility. Wood et al. (2004)
The Estimated Impact on Philadelphia:
Medical Analysis - Each year a CUES that saw 2000 patients would lead to an estimated 
prevention of:
 3 to 48 cases of HIV infections annually 
 15 to 213 cases of Hepatitis C annually 
 24 to 76 overdose related deaths 
Economic Analysis- Estimate of the impact of a hypothetical CUES in Philadelphia
 Reduction in costs related to hospitalizations for Skin and Soft tissue infections
were estimated to be $1.5 – $1.9 Million annually. 
 Total value of overdose deaths averted: $12.5 to $74.8 Million annually
 Estimated Impact on Healthcare costs annually: 
 A reduction in ambulance costs by $123,776 per year
 Annual savings of $280,683 due to a reduction in in hospital emergency 
department utilization 
 Annual savings of $271,971 on hospital costs due to reduced hospitalizations
for those who overdose 
Ethical Analysis - revealed that safe injection is ethically permissible given the primary 
intent is to limit the user’s exposure to harm. 
 Reviewing existing evidence on Supervised Injection facilities and local data we 
estimate the following harm reduction impact:
 Serves as an access point for drug and alcohol treatment
 Reduced incidence of disease transmission as well as drug overdose
Philadelphia Dept. of Public Health (2017)
